Background
Long term safety and virologic outcomes, therapeutic drug monitoring and patient reported outcomes on health-related quality of life and treatment satisfaction of CAB-RPV LA in routine clinical care have rarely been described
Methods
In the ANRS CO3-AQUIVIH-NA observational cohort in South-Western France, all adults living with HIV who received their first CAB + RPV LA injection from January 1st 2022 were included. Virologic failure (VF) was defined as 1 HIV RNA > 1000 cp/mL or 2 consecutive HIV RNA > 50 cp/mL; or no HIV RNA < 50 cp/mL at 6 months in PWH not virologically suppressed (VS) at baseline. Patients referring to the hospital pharmacy for their drug delivery were proposed a questionnaire on their health-related quality of life (HR-QOL) under CAB-RPV LA and their treatment satisfaction.
Results
Among 453 people with HIV-1 (PWH) who received at least one injection of CAB + RPV LA, 433 (96%) were VS at baseline. 9 had a VL between 50 and 200 cp/mL and 11 > 200. At initiation, PWH had a median age of 47 years (IQR 37-55), 26% were women, 76% born in France and 14% in Sub-Saharan Africa, 1% had HIV sub-type A1, a median BMI of 24·9 kg/m2 (IQR 22.5-28.0) and 15% had BMI>30. Median LDL-C was 3.1 mmol/L. PWH were diagnosed with HIV for a median of 12.5 (IQR 6.5-20.8) years. They were followed for a median time of 20.7 (IQR 11.7-27.5) months. 58 PWH (12.8%) had discontinued treatment, 10 for VF (2.2%), 20 (4.4%) for adverse events (6 (1.3%) for injection site reactions). 2 VF were in fact low level viremias. At VF, 6 had no resistance-associated mutations detected, 4 had both NNRTI and INsTI resistance-associated mutations (0.1%). Among these 4, 1 was not VS at baseline (HIV-RNA: 63.800 copies/mL) and had undetectable RPV and CAB plasma concentrations at the end of lead-in. All 4 had low RPV (< 50 ng/mL) and CAB (< 1000 ng/mL) plasma concentrations at some time during the drug monitoring, 2 had BMI> 30 (32 and 36). No significant changes in BMI nor LDL-C were observed. In the subgroup of 63 PWH responding to the questionnaire, the score of HR-QOL was improved in 75% of them with a high treatment satisfaction.
Conclusions
In this large French cohort, 87% of PWH continued CAB + RPV LA injections at 3 years and virologic control was maintained in 98% of them. These results suggest that CAB + RPV LA injectable can be administered effectively during routine clinical care on a long period with no major impact on BMI and metabolic parameters and high HR-QOL score and treatment satisfaction.